Home Nav
Nextech Invest Logo

Lukas Rindlisbacher

Alfred Scheidegger

Lukas Rindlisbacher completed an B.Sc. specializing in molecular cell biology in 2016, and a Master of Molecular Health Science in 2018, both from ETH Zurich, Switzerland. During his master thesis in the lab of Prof. Neri, he gained scientific experience in biology with specialization on bispecific antibodies.

 

Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close